drugset / Trial / NCT02326142
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to assess the efficacy of a single dose of OBE001, an oral oxytocin antagonist, given for up to 7 days to delay preterm birth by 7 days compared to placebo.
Timeline
- Start
- 2015-03
- Primary completion
- 2016-10
- Completion
- 2017-10
Outcome
Outcome not reported
Stopped: “Enrolment difficulties.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nolasiban | Small molecule | — | Oral |
Indications
No indication recorded.